Vytan

Valsartan

HTN, heart failure, post MI.

HTN 80 or 160 mg once daily, may be increased to 320 mg once daily or diuretic may be added. Heart failure Initially 40 mg bd, up-titrated to 80 & 160 mg bd as tolerated. Max: 320 mg daily in divided doses. Post MI Initially 20 mg bd, up-titrated to max: 160 mg bd as tolerated.

May be taken with or without food.

Hypersensitivity. Concomitant use w/ aliskiren in patients w/ type 2 DM. Severe hepatic impairment; biliary cirrhosis, cholestasis. Pregnancy.

Discontinue use & not to be re-administered in patients w/ history of angioedema. Not to be used in primary hyperaldosteronism. Not recommended in dual blockade of renin-angiotensin-aldosterone system. Risk of hypotension in Na &/or vol-depleted patients; bilateral renal artery stenosis or stenosis to solitary kidney; aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy; severe CHF. Regularly monitor K levels, renal function, electrolytes & BP. Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption. Not recommended in concomitant use w/ K supplements, K-sparing diuretics, K-containing salt substitutes or other agents increasing K levels eg, heparin. Kidney transplantation; severe renal impairment (CrCl <10 mL/min), patients undergoing dialysis. Mild to moderate hepatic impairment w/o cholestasis. Not to be used during 2nd & 3rd trimesters of pregnancy. Not recommended during lactation. Childn & adolescents <18 yr.

Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.

Increased lithium conc & toxicity. Increased K levels w/ K supplements, K-sparing diuretics, K-containing salt substitutes or other substances increasing K levels. Attenuated antihypertensive effect w/ NSAIDs including selective COX-2 inhibitors, ASA.

Angiotensin II Antagonists

C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

B